SectorBiological Technology
Established Date16/12/2013
Listing Date07/04/2016
ExchangeNASDAQ Stock Exchange
Full-time Employees102
Fiscal Year Ends31/12
Security TypeCommon stock
Office address221 Crescent Street , Building 23 , Suite 105 , Waltham, MA 02453
Business
IntroductionSpyre Therapeutics, Inc., was converted from a Delaware limited liability company on December 16, 2013. The company is a biotechnology company that aims to create the next generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational treatment combinations, and precision medical approaches for patient selection. Spyre's product line includes extended half-life antibodies against α4β7, TL1A and IL-23.
